<document>
 <table id="Table 1">
  <caption text="

   Benefits and challenges in the development of co-formulated drug products
  
">
  </caption>
  <legend text="

   DS: drug substance, CMC: Chemistry Manufacturing &amp; Control, PK: pharmacokinetics, PD: pharmacodynamics, SC: subcutaneous, IV: intravenous, BLA: biologics license application.
  
">
  </legend>
  <row row="0">
   <cell col-end="0" col-start="0" row-end="0" row-start="0" text="Characteristics">
   </cell>
   <cell col-end="1" col-start="1" row-end="0" row-start="0" text="Pre-condition">
   </cell>
   <cell col-end="2" col-start="2" row-end="0" row-start="0" text="Risk">
   </cell>
  </row>
  <row row="1">
   <cell col-end="0" col-start="0" row-end="1" row-start="1" text="Single instead of multiple drug product delivered to the patient, increasing compliance while reducing medical error">
   </cell>
   <cell col-end="1" col-start="1" row-end="1" row-start="1" text="Proven synergistic medical benefit and safety from combinational clinical trials">
   </cell>
   <cell col-end="2" col-start="2" row-end="1" row-start="1" text="Possible reduction in dosage flexibility
     
     Number of patients that can accept combination therapy could show population and disease variance">
   </cell>
  </row>
  <row row="2">
   <cell col-end="0" col-start="0" row-end="2" row-start="2" text="Simplified CMC and logistics">
   </cell>
   <cell col-end="1" col-start="1" row-end="2" row-start="2" text="Integration in process development
     
     Stability of each DC does not change significantly in the mixture
     
     Analytics to characterise the degradation of individual drug component in the mixture">
   </cell>
   <cell col-end="2" col-start="2" row-end="2" row-start="2" text="More complex control strategy
     
     Availability of analytics
     
     Change in delivery route if co-formulated products have lower concentration tolerance (
     
      e.g.
     
     from SC to IV)
     
     Additional clinical trials are needed to prove the safety of co-formulated products">
   </cell>
  </row>
  <row row="3">
   <cell col-end="0" col-start="0" row-end="3" row-start="3" text="New market/product differential strategy">
   </cell>
   <cell col-end="1" col-start="1" row-end="3" row-start="3" text="Potential IP extension of existing drugs">
   </cell>
   <cell col-end="2" col-start="2" row-end="3" row-start="3" text="New regulation landscape needs to be introduced (potential delay in BLA approval)">
   </cell>
  </row>
  <statements>
   <statement id="0" text="A few co-formulated biologic-based products that have been recently approved or are under clinical development suggests an increasing interest in industry to combine biologic therapeutic agents into a single dosage form ( Table 2 )." type="">
   </statement>
   <statement id="6" text="Risk New regulation landscape needs to be introduced (potential delay in BLA approval)Characteristics is New market/product differential strategy." type="">
   </statement>
  </statements>
 </table>
</document>